| Literature DB >> 28533481 |
Ren-Chin Wu1, An-Shine Chao2, Li-Yu Lee1, Gigin Lin3, Shu-Jen Chen4, Yen-Jung Lu4, Huei-Jean Huang2,5, Chi-Feng Yen2, Chien Min Han2, Yun-Shien Lee6, Tzu-Hao Wang2,5, Angel Chao2,5.
Abstract
Benign metastasizing leiomyoma (BML) is a rare disease entity typically presenting as multiple extrauterine leiomyomas associated with a uterine leiomyoma. It has been hypothesized that the extrauterine leiomyomata represent distant metastasis of the uterine leiomyoma. To date, the only molecular evidence supporting this hypothesis was derived from clonality analyses based on X-chromosome inactivation assays. Here, we sought to address this issue by examining paired specimens of synchronous pulmonary and uterine leiomyomata from three patients using targeted massively parallel sequencing and molecular inversion probe array analysis for detecting somatic mutations and copy number aberrations. We detected identical non-hot-spot somatic mutations and similar patterns of copy number aberrations (CNAs) in paired pulmonary and uterine leiomyomata from two patients, indicating the clonal relationship between pulmonary and uterine leiomyomata. In addition to loss of chromosome 22q found in the literature, we identified additional recurrent CNAs including losses of chromosome 3q and 11q. In conclusion, our findings of the clonal relationship between synchronous pulmonary and uterine leiomyomas support the hypothesis that BML represents a condition wherein a uterine leiomyoma disseminates to distant extrauterine locations.Entities:
Keywords: benign metastasizing leiomyoma; clonality; massively parallel sequencing; molecular inversion probe array
Mesh:
Substances:
Year: 2017 PMID: 28533481 PMCID: PMC5564585 DOI: 10.18632/oncotarget.17708
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Clinicopathological and immunohistochemical analyses of three pairs of synchronous uterine and lung leiomyomas
| case 1 | case 2 | case 3 | |
|---|---|---|---|
| Age (years) | 35 | 37 | 46 |
| Interval (months)a | −2 (lung first) | −1(lung first) | 0 (simultaneously) |
| Largest lung tumor (mm) | 13 | 9 | 36 |
| Number of lung tumors | miliary | multiple | multiple |
| Atypia | Negative | Negative | Negative |
| Necrosis | Negative | Negative | Negative |
| Mitosis | Negative | Negative | Negative |
| ER | Positive | Positive | Positive |
| PR | Positive | Positive | Positive |
| SMA | Positive | Positive | Positive |
| desmin | Positive | Positive | Positive |
| CD34 | Negative | Negative | NA |
| CD10 | Negative | NA | focal |
| S-100 | Negative | Negative | NA |
| HMB-45 | Negative | NA | NA |
| CD117 | NA | Negative | Negative |
a Interval between the detection of lung tumors and uterine tumor
NA: not applicable.
Figure 1Representative case of a synchronous lung and uterine leiomyomata (case 1)
(A) Computed tomography scan displaying multiple, well-defined nodules in randomized distribution over bilateral lung bases. The maximal dimension of the nodules is 13 mm (red arrows). (B) Photomicrograph of a pulmonary leiomyoma. The inset shows that the pulmonary leiomyoma was composed of fascicles of bland-looking spindle cells. (C) Synchronous uterine leiomyoma exhibiting similar histology as the pulmonary leiomyoma. Immunohistochemically, the pulmonary leiomyoma was diffusely positive for (D) estrogen receptor and (E) progesterone receptor.
Single nucleotide variants and short insertion /deletions of three pairs of synchronous uterine and lung leiomyomas identified using a comprehensive cancer panel containing 409 cancer-related exons
| Gene | DNA change | Protein change | case 1 | case 2 | case 3 | |||
|---|---|---|---|---|---|---|---|---|
| Uterus | Lung | Uterus | Lung | Uterus | Lung | |||
| ATM | c.6198+3A>G | splice_region | 0.0% | 16.5% | ||||
| BCL11B | c.1093C>T | p.R365W | 10.3% | 5.2% | ||||
| DNMT3A | c.2206C>T | p.R736C | 42.8% | 28.8% | ||||
| FANCD2 | c.1401_1402invGT | p.Y468H | 7.5% | 3.9% | ||||
| HCAR1 | c.675G>T | p.V225V | 0.0% | 11.9% | ||||
| LRP1B | c.3099C>A | p.D1033E | 18.9% | 0.0% | ||||
| MSH6 | c.1968C>G | p.P656P | 42.9% | 25.4% | ||||
| MYH11 | c.1402-2A>T | splice_acceptor | 13.5% | 0.0% | ||||
| NTRK3 | c.685A>G | p.I229V | 0.0% | 7.4% | ||||
| SYNE1 | c.19055C>T | p.A6423V | 7.4% | 3.4% | ||||
Percentage indicates variant frequency of the mutation
Figure 2Copy number variations in three pairs of synchronous pulmonary and uterine leiomyomata
Blue and red blocks represent chromosome gains and losses, respectively. The synchronous tumors from case 2 shared three identical long-segment chromosome losses localized at chromosomes 3q, 11q, and 15q.
Figure 3Details of the shared copy number variations identified in the uterine (left panel) and pulmonary (right panel) leiomyoma from case 2
For each aberrant chromosome, the chromosome ideograms (top), log2 ratio (middle), and B allele frequency (bottom) are shown. All three segments of chromosome loss (red bar) had identical or very close breakpoints between uterine and pulmonary leiomyomas.
Copy number aberrations (CNAs) of benign metastasizing leiomyomas in the literature and the present study
| Author | Method | Number of cases | CNVa |
|---|---|---|---|
| Lin [ | Single Nucleotide Polymorphism 6.0 | 1 | No imbalance (2) |
| Bowen [ | 250K Nsp Assay Kits | 1 | Loss in 1p36.33–p36.23 (2),1p36.13–p35.2 (2), 2q37.3 (2), |
| Nucci [ | Karyotyping | 5 | Gain in 1p11 (1), 1p21 (1), 1p35 (1), 2p25 (1), 6p21-p22 (1), 7q36 (1), 12q22-q24 (1), 13p10 (1), chr16 (1), 19q13 (1), 19q13.3 (1), 22q12 (1), 22q13 (1), chr22 (1) Loss in chr2 (1), |
| Tietze [ | Competitive hybridization of fluorescein isothiocyanate-labeled tumor DNA | 1 | No imbalance (2) |
| Present study | Molecular inversion probe array (OncoScan) | 3 | Loss in |
a Brackets show the number of specimens.
Recurrent copy number aberrations are shown in block letters, i.e. chromosome 3q, 11q, and 22q.